{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218192","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2026-05-12T11:33:15+00:00","discovered_at":"2026-05-12T11:35:00.340358+00:00","generated_at":"2026-05-12T11:36:36.839264+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mereo BioPharma Q1 2026 net loss $6.7M; setrusumab regulatory dialogue initiated for pediatric OI","bullets":["Net loss $6.7M vs $12.9M YoY; cash $36.2M as of March 31, expected runway into mid-2027.","Setrusumab Phase 3 studies missed primary fracture endpoint but achieved significant bone mineral density and PRO improvements; regulatory engagement for pediatric OI started.","Alvelestat partnership discussions ongoing; single Phase 3 trial (~220 patients) could start within 6 months of deal.","Vantictumab Phase 2 in osteopetrosis expected H2 2026 by partner āshibio; Mereo retains European rights.","R&D expenses $4.7M (+$0.8M YoY) driven by setrusumab manufacturing costs; G&A $4.0M (-$3.3M) due to ADR reimbursement and savings."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218192","json":"https://secwatch.observer/filing/0001193125-26-218192.json","markdown":"https://secwatch.observer/filing/0001193125-26-218192.md","text":"https://secwatch.observer/filing/0001193125-26-218192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526218192/0001193125-26-218192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526218192/mreo-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:36:36.839264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e9d2e8f96d1ab848b01926dd4d972d86faeb5c5","claim":"Mereo BioPharma Group plc reported the first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $6.7 million.","evidence_excerpt":"On May 12, 2026, Mereo BioPharma Group plc announced its financial results for the first quarter ended March 31, 2026 and provided an update on recent corporate developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526218192/0001193125-26-218192-index.htm","confidence":0.75,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss for the first quarter of 2026 was $6.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}